RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Zhejiang Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07689929, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. Not stated to Not stated; sex: women only

    Registered eligibility fields

  2. Advanced breast cancer confirmed by pathology (AJCC 8th edition, stage IV);

    Inclusion criterion 3

    Signed informed consent, agreeing to provide clinical info like imaging and pathology data before and after treatment.

    Inclusion criterion 11

  3. Received at least 2 cycles of Pyrotinib monotherapy;

    Inclusion criterion 5

    Planning to receive Pyrotinib monotherapy as second-line or later treatment; if HER2-positive, previously received neoadjuvant/adjuvant H(P) therapy, and had metastatic recurrence within 12 months after completing treatment, with post-recurrence anti-HER2 therapy considered second-line treatment.

    Inclusion criterion 10

    Previous treatment with other HER2-ADC drugs;

    Exclusion criterion 3

  4. Efficacy assessed according to RECIST 1.1, with follow-up data (PFS or ORR).

    Inclusion criterion 7

  5. History of other malignancies (except non-melanoma skin cancer or cases with no recurrence for over 5 years);

    Exclusion criterion 4

  6. Pregnant or breastfeeding women;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07689929, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Retrospective Cohort (Modeling and Validation):
  • Female, 18 years or older;
  • Advanced breast cancer confirmed by pathology (AJCC 8th edition, stage IV);
  • HER2 status known;
  • Received at least 2 cycles of Pyrotinib monotherapy;
  • Complete baseline IHC slides (HER2, ER, PR, Ki-67) and HE-stained slides;
  • Efficacy assessed according to RECIST 1.1, with follow-up data (PFS or ORR).
  • Prospective Cohort (External Validation):
  • Meet criteria 1-3 above;
  • Planning to receive Pyrotinib monotherapy as second-line or later treatment; if HER2-positive, previously received neoadjuvant/adjuvant H(P) therapy, and had metastatic recurrence within 12 months after completing treatment, with post-recurrence anti-HER2 therapy considered second-line treatment.
  • Signed informed consent, agreeing to provide clinical info like imaging and pathology data before and after treatment.

Exclusion Criteria:

  • All cohorts:
  • Baseline IHC or HE slides of poor quality (e.g., faded, folded, or tissue loss >10%);
  • Previous treatment with other HER2-ADC drugs;
  • History of other malignancies (except non-melanoma skin cancer or cases with no recurrence for over 5 years);
  • Participation in other interventional clinical trials at the same time (past trials already completed are fine);
  • Lost to follow-up or missing key clinical data during treatment (e.g., efficacy evaluation, dose adjustment records);
  • Special treatment backgrounds that the AI model cannot analyze (e.g., combined local radiotherapy, severe infections, or other confounding factors).
  • Additional exclusions for the prospective cohort:
  • Pregnant or breastfeeding women;
  • Contraindications to Üher (e.g., history of ILD, left ventricular ejection fraction <50%, etc.);
  • Unable to comply with regular follow-up (e.g., living in a remote area, mental disorders).

Quoted from ClinicalTrials.gov, NCT07689929, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07689929, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07689929